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RESULTS: In our study sample, 25.4%were on polypharmacy, and 75% reported use
of 0 to 5 drugs. In the multivariate model, individuals with either one or two clus-
ters of conditions were significantly less likely to be on polypharmacy than those
with multimorbidity with all the three clusters. The adjusted odds ratio (AOR)
ranged from 0.06 to 0.69. Compared to individuals with multimorbidity with two
clusters (respiratory and musculoskeletal), individuals without multimorbidity
were as likely to be on polypharmacy. Also polypharmacy varied with the type of
cluster of conditions in another multivariate model, being more prominent in in-
dividuals with cardio-metabolic cluster of conditions. CONCLUSIONS: Polyphar-
macy varies with the type of cluster of conditions. Our findings suggest that there
is a higher medication burden in individuals with multimorbidity with at least one
cardio-metabolic condition.
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OBJECTIVES: To determine the association of primary care availability and health
insurance coveragewith PreventableHospitalizations (PHs) and to examine if these
relationships vary by chronic or acute nature of the underlying condition.
METHODS: Preventable hospitalizations (PHs) as defined by Agency of Healthcare
Research and Quality (AHRQ) were identified from the Texas Health Care Informa-
tion Collection (THCIC) Inpatient Discharge Data. The study was restricted to non-
elderly adult residents of Harris County, TX,with at least one inpatient discharge in
2008. The dependent variable was a binary PH variable, which was further segre-
gated into chronic and acute PHs. The primary independent variableswere primary
care physician and safety net clinic availability (measured as number of physi-
cians/clinics within a 5-mile radius of patient’s ZIP code per 1000 population) and
health insurance.Multivariable logistic regressionwas used to determine the effect
of independent variables on PHs. RESULTS: The study population had 11,313 PHs in
2008, of which 7,236 (64%) were for chronic conditions. Physician availability did
not affect the risk of PHs. Safety net availability was significantly associated with
overall PH risk, but only in the uninsured. An increase in safety net availability by
one clinic per 1000 population led to a 23% decline in odds of uninsured PHs. Lack
of health insurance was associated with increased PH odds of 30%. However, when
chronic and acute PHswere examined separately, safety net availability and health
insurance were associated with risk of PHs only for chronic conditions, and had no
significant effect on the risk of acute PHs. CONCLUSIONS: Expansions in primary
care safety net availability or health insurance coveragemay reduce the risk of PHs,
especially for chronic conditions. Hence, it is important that both of these strate-
gies be addressedwhile designing policies to increase access and reduce PHs in the
community.
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OBJECTIVES: Cancer outcomes in the United Kingdom are inferior to those in
France, which may be attributable to less effective screening, later diagnoses and
longer waiting times. But access to state-of-the-art medicinesmay also be a factor.
This poster aims to compare access to orphan oncology drugs in France, where the
HTA evaluation is based on clinical effectiveness, and the UK, which employs a
cost-effectiveness approach.METHODS:We identified a total of 33 EMA-approved
orphan oncology indications. To ensure a homogeneous sample, we excluded all
those targeting non-therapeutic indications, as well as those not reviewed by
France’s Transparency Commission (TC), the National Institute for Health and
Clinical Excellence (NICE) in England and Wales, and the Scottish Medicines Con-
sortium (SMC). This left a total of 24 orphan indications. To determine a relation-
ship in the outcomes of the Health Technology Assessments (HTAs) in France and
the United Kingdom, we developed a scoring system based on the ASMR rating
awarded by the TC in France and the recommendations provided by NICE and/or
the SMC in the United Kingdom. RESULTS: Although prices are similar, access to
orphan oncology drugs is far greater in France than the UK. Of the 24 indications in
our sample, NICE recommended just five for the NHS in England and Wales (an
additional two were made available through the Cancer Drug Fund). In Scotland,
the SMC recommended seven of them, but only two for unrestricted use. By con-
trast, 23 out of the 24 indications are reimbursed in France. Regression analysis on
the HTA outcomes scores revealed no relationship between the ASMR scores
awarded and the verdicts fromNICE and/or the SMC (r2 0.002). CONCLUSIONS: In
its proposed transition to value-based pricing, the UK Government has the oppor-
tunity to revise its HTA process to make innovative cancer drugs available to more
patients.
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OBJECTIVES: Access to health care for indigent population in Ghana remains a
challenge despite introduction of the National Health Insurance Scheme (NHIS) in
2004 to address the problem of financial barriers to health care access. The situa-
tion is worse in rural settlements where there are inadequate or no health care
facility and health care professionals. The Ada Kofe community is a fishing com-
munity in the Tema Metropolis with most of the inhabitants fully engaged in fish-
ing as their source of livelihood. The community has no primary health care facility
and as result inhabitants face geographical and financial difficulties when access-
ing health care. The study aimed to explore access to health care services in Ada
Kofe community.METHODS: Face-to-face interviewmethod was employed to col-
lect data on health insurance cover, usual source of care, and other barriers to
health care access in the community using semi-structured questionnaire.
RESULTS: About 45% of the respondents had health insurance cover. Although
most households had usual place of ongoing care, 56.7% specifically used hospital
OPD outside the community for their health care needs. This creates financial and
geographical difficulties which in extreme cases may lead to avoidable deaths.
About one-third of the respondents faced financial, structural, and personal barri-
ers when accessing health care in the community due to lack of health care facil-
ities and health insurance cover. CONCLUSIONS:More than half of the households
in the community do not have health insurance cover. Moreover, the community
has no primary health care center and as a result household members travel out-
side the community to access health care. An establishment of NHIS registration
centre in the community will increase enrolment and facilitate access to health
care. Provision of community health centre will also help remove some of the
financial barriers households faced when accessing care.
PHP30
THE BITTERSWEET SUCCESS OF ORPHAN DRUGS
Bernard L, Grima DT, Cameron HL
Cornerstone Research Group, Burlington, ON, Canada
OBJECTIVES: Legislation such as the Orphan Drug Act (ODA) in the United States
(US), and Regulation 141/2000 in the European Union (EU) have been successful in
stimulating research and development and supporting regulatory approval of or-
phan drugs that would not have otherwise been commercially viable. This success,
however, has been bittersweet. While increasing numbers of patients with rare
diseases have gained access to potentially life-saving or life-extending treatments,
decision makers have struggled to mitigate the impact of expensive orphan drugs
on overall drug and healthcare budgets. The objective of this studywas two-fold; 1)
to explore the impact of orphan drug legislation on patient access to drugs for rare
diseases in the US and EU, and 2) to quantify the impact of costs associated with
orphan drugs on overall drug and healthcare budgets in the US and EU.METHODS:
An exhaustive literature search was performed to identify orphan drugs which are
currently funded in the US or EU, determine the prevalence of orphan diseases
treated by these drugs, identify the costs associated with these drugs, and explore
the impact of these costs on overall drug and healthcare budgets. Literature
searches were conducted using various search engines, including PubMed, Google,
and Google Scholar. RESULTS: Legislative initiatives directed at drugs for rare dis-
eases in the US and EU have resulted in the development and funding of an un-
precedented number of drugs for rare diseases. The recent approval of a multitude
of new drugs for rare diseases in the US and EU has led to notable increases in
overall drug and healthcare budgets. CONCLUSIONS: Reimbursement and patient
access for orphan drugs will become increasingly more challenging as decision
makers become more prohibitive in their approval of new and expensive drugs.
Criterion for the reimbursement of drugs for rare diseases needs to be clearly
established and communicated.
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OBJECTIVES: According to state legislation free provision of medicines for War
Veterans and Chernobyl Victims is available in Ukraine. Since 2009, Ukraine intro-
duced the drug formulary system by the Central and Regional formulary
committees. METHODS: To asses the comparability of two different formulary
committees work results we analyzed 2010 Formulary lists by the State Medical
Centre for War Veterans and the Kyiv Regional health care program for people
affected by the Chernobyl accident. Also, we determined the following indicators
for each formulary list: total annual budget value; annual budget value per person;
number of INNs (international nonproprietary names); total number of brands;
average number of brands per INN ( SD); budget shares of “original” drugs versus
“generics”; pack (unit) shares of “original” drugs versus “generics”. RESULTS:Anal-
ysis of War Veterans formulary list (WVFL) and Kyiv regional Chernobyl program
formulary list (KCFL) showed the following results total annual budget value for
WVFL was $813,984.6 USD, for KCFL – $2,049,038.4 USD ($1 USD  7.99 UAH on
01.15.2012); annual budget value per person for WVFL was $81.45 USD, for KCFL -
$3.03 USD; number of INNs inWVFL and KCFL were 314 and 398, respectively; total
number of brands were 486 and 582, respectively; average number of brands per
INN ( SD) were 1.15 ( 0.47) and 1.36 ( 0.29), respectively; budget shares of
“original” drugs versus “generics” inWVFL and KCFLwere 30% versus 70% and 36%
versus 64%, respectively; Pack (unit) shares of “original” drugs versus “generics”
were 6% versus 94% in both. CONCLUSIONS: Results show that despite the differ-
ences in volumes of the budgeting, the structures of formulary lists were compa-
rable because of the centralization of the decision-making process in formulary
committees. It is necessary to optimize formulary lists for War Veterans and Cher-
nobyl on the costs and the number of original drugs.
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